Clinical trials: Obesity/therapy
Obesity
MOTIVATE Weight Loss Study
The purpose of this study is to evaluate the impact of minor variations in Incisionless Operating Platform (IOP)procedural techniques on gastric emptying, hormone levels, satiety, and weight loss in the treatment of primary…
- Trial name
- MOTIVATE (NCT01679158)
- Testing
- Using The IOP system from USGI to place suture anchors
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- USGI Medical
Overweight , Obesity, Adults
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.
- Trial name
- PRESERVE (NCT07837973)
- Testing
- ALV-100
- Where
- 20 sites in United States
- Volunteers
- 220 people
- Sponsor
- Alveus Therapeutics, Inc.
Obesity
Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study
This research study is being performed to find out if a new device, AspireAssist Aspiration Therapy System, can help people with obesity to lose weight without causing too many side effects.
- Trial name
- PATHWAY (NCT01766037)
- Testing
- Aspiration Therapy (AspireAssist), Lifestyle Therapy
- Where
- 10 sites in United States
- Volunteers
- 171 people
- Sponsor
- Aspire Bariatrics, Inc.
Obesity, Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Topiramate in the Treatment fo Obese, Type 2 Diabetic Patients Treated With Metformin
The purpose of this study is to compare the efficacy (in terms of weight and hemoglobin type A1c [HbA1c]) and safety of topiramate (96 milligrams[mg] or 192 mg daily) with placebo in the treatment of obesity in Type 2 diabetic…
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231660
- Testing
- topiramate
- Volunteers
- 211 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity
Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults
The purpose of this study is to evaluate efficacy of orlistat 60 mg as adjuvant treatment of Obesity in adults.
- Trial name
- NCT01755676
- Testing
- Orlistat 60 mg
- Where
- 5 sites in Brazil
- Volunteers
- 638 people
- Sponsor
- EMS
Obesity
Vagal Blocking for Obesity Control
To determine the safety, efficacy and treatment algorithm(s) of the Maestro System in causing weight loss in obese subjects - This study will provide feasibility data regarding the potential of intra-abdominal vagus nerve…
- Trial name
- NCT00555958
- Testing
- Active, implantable, intra-abdominal vagal blocking medical device
- Where
- 5 sites in Australia, Mexico and 2 more
- Volunteers
- 120 people
- Sponsor
- ReShape Lifesciences
Obesity, Overweight
THE ENLIGHTEN STUDY
The primary objective of this study is to demonstrate the safety and efficacy of the Elipse Gastric Balloon System for the treatment of obese adults.
- Trial name
- NCT03261453
- Testing
- Active Elipse Device
- Where
- 12 sites in United States
- Volunteers
- 400 people
- Sponsor
- Allurion Technologies
Obesity, Primary
A Feasibility Study for the Treatment of Primary Obesity Cross-over Arm
Cross-over arm of the pilot study evaluating a treatment for obesity.
- Trial name
- NCT05939973
- Testing
- g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- USGI Medical
Obesity, Diabetes Mellitus, Type 2
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects…
- Trial name
- NCT05925920
- Testing
- ENT-03
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Metabolics Pharma
Dyslipidemia, Obesity
An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients
The purpose of this study is to assess the effect of rimonabant 20 mg on HDL (high density lipoprotein) cholesterol and on TG (triglycerides) plasma levels over a period of one year when prescribed with a hypocaloric diet (600…
- Trial name
- ADAGIO-lipids (NCT00239967)
- Testing
- Rimonabant (SR141716)
- Where
- 14 sites in United States, Australia and 12 more
- Volunteers
- 803 people
- Sponsor
- Sanofi
Overweight, Obesity
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake.
- Trial name
- NCT06267092
- Testing
- No treatment given, Cagrilintide and Semaglutide
- Where
- Germany
- Volunteers
- 164 people
- Sponsor
- Novo Nordisk A/S
Obesity
Effects of Red Light LED Therapy on Body Contouring
The purpose of this study is to determine whether red light therapy using LED 650nm red light for body contouring of the waist, hips and thighs is as effective as red light therapy using Laser 635nm red light.
- Trial name
- NCT03242564
- Testing
- Vevazz LED
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Vevazz, LLC
Diabetes Mellitus, Type 2
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with…
- Trial name
- MARITIME-T2D-3 (NCT07866066)
- Testing
- Maridebart cafraglutide, Semaglutide
- Volunteers
- 1,300 people
- Sponsor
- Amgen
Obesity, Behavior, Health
Evaluation of Brain Activity Changes After a Behavior Change Weight Loss Intervention
The aim of this study is to compare brain changes in individuals with overweight or obesity enrolled in either the Noom Healthy Weight program or a matched control.
- Conditions
- Obesity, Behavior, Health, Weight Loss
- Trial name
- NCT04522245
- Testing
- Noom Healthy Weight; mobile behavior change program for weight loss., Matched Control
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Obesity, Weight Gain
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related…
- Trial name
- NCT06439277
- Testing
- Tirzepatide
- Where
- 69 sites in United States, Argentina and 10 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Obesity
Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients
To assess safety of Dietressa in the dose of 6 tablets daily within 24 weeks in treatment of obese patients (BMI 35,0-39,9 kg/m2).
- Trial name
- NCT01570829
- Testing
- Dietressa
- Where
- 17 sites in Russia
- Volunteers
- 331 people
- Sponsor
- Materia Medica Holding
Healthy Participants
A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations
The purpose of this study is to assess the relative bioavailability of a single dose AZD5004 in healthy participants, among 3 different oral tablet formulations.
- Trial name
- NCT06996886
- Testing
- AZD5004
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
This trial is conducted in Europe. The aim of this clinical trial is to compare the change in trunk fat mass, assessed by Double Energy X-ray Absorptiometry (DEXA) after 26 weeks of treatment with insulin detemir or insulin NPH…
- Trial name
- NCT00795600
- Testing
- insulin detemir, insulin NPH
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Schizophrenia, Psychotic Disorders
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity.
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- NCT00044187
- Testing
- Sibutramine
- Where
- 16 sites in United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM
GSK1070806 is a humanised IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18). The aims of this placebo controlled study are to evaluate the efficacy, safety, tolerability, pharmacokinetics…
- Trial name
- T2DM (NCT01648153)
- Testing
- GSK1070806
- Where
- 13 sites in Spain, United Kingdom
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline